No retraction, correction or concern found when last checked on Oct 30, 2026.

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Zijun Wang, Frauke Muecksch, Dennis Schaefer-Babajew and 25 more

Nature · 2021 · CC BY

Abstract

More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult to control despite the availability of several working vaccines. Progress in controlling the pandemic is slowed by the emergence of variants that appear to be more transmissible and more resistant to antibodies 1,2 . Here we report on a cohort of 63 individuals who have recovered from COVID-19 assessed at 1.3, 6.2 and 12 months after SARS-CoV-2 infection, 41% of whom also received mRNA vaccines 3,4 . In the absence of vaccination, antibody reactivity to the receptor binding domain (RBD) of SARS-CoV-2, neutralizing activity and the number of RBD-specific memory B cells remain relatively stable between 6 and 12 months after infection. Vaccination increases all components of the humoral response and, as expected, results in serum neutralizing activities against variants of concern similar to or greater than the neutralizing activity against the original Wuhan Hu-1 strain achieved by vaccination of naive individuals 2,5–8 . The mechanism underlying these broad-based responses involves ongoing antibody somatic mutation, memory B cell clonal turnover and development of monoclonal antibodies that are exceptionally resistant to SARS-CoV-2 RBD mutations, including those found in the variants of concern 4,9 . In addition, B cell clones expressing broad and potent antibodies are selectively retained in the repertoire over time and expand markedly after vaccination. The data suggest that immunity in convalescent individuals will be very long lasting and that convalescent individuals who receive available mRNA vaccines will produce antibodies and memory B cells that should be protective against circulating SARS-CoV-2 variants.

References 53

1.
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England · 2021
No notice
2.
Wang Z, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616-622.
Not in our library10.1038/s41586-021-03324-6
3.
Robbiani DF, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437-442.
Not in our library10.1038/s41586-020-2456-9
4.
Gaebler C, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639-644.
Not in our library10.1038/s41586-021-03207-w
5.
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination · 2021
No notice
6.
Saadat S, et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. J. Am. Med. Assoc. 2021;325:1467-1469.
Not in our library10.1001/jama.2021.3341
7.
Krammer F, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 2021;384:1372-1374.
Not in our library10.1056/nejmc2101667
8.
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose · 2021
No notice
9.
Muecksch, F. et al. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. Preprint at 10.1101/2021.03.07.434227 (2021).
Not in our library10.1016/j.immuni.2021.07.008
10.
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability · 2020
No notice
11.
Cao Y, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020;182:73-84.
Not in our library10.1016/j.cell.2020.05.025
12.
Ju B, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115-119.
Not in our library10.1038/s41586-020-2380-z
13.
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses · 2020
No notice
14.
Tegally H, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438-443.
Not in our library10.1038/s41586-021-03402-9
15.
West, A. P. et al. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. Preprint at 10.1101/2021.02.14.431043 (2021).
Not in our library10.1038/s41467-021-25168-4
16.
Inoue T, et al. Exit from germinal center to become quiescent memory B cells depends on metabolic reprograming and provision of a survival signal. J. Exp. Med. 2021;218:e20200866.
Not in our library10.1084/jem.20200866
17.
Viant C, et al. Antibody affinity shapes the choice between memory and germinal center B cell fates. Cell. 2020;183:1298-1311.
Not in our library10.1016/j.cell.2020.09.063
18.
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model · 2020
No notice
19.
Kreer C, et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell. 2020;182:1663-1673.
Not in our library10.1016/j.cell.2020.08.046
20.
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection · 2021
No notice
21.
Sokal A, et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell. 2021;184:1201-1213.
Not in our library10.1016/j.cell.2021.01.050
22.
Prolonged evolution of the human B cell response to SARS-CoV-2 infection · 2021
No notice
23.
Barnes CO, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588:682-687.
Not in our library10.1038/s41586-020-2852-1
24.
Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.
Not in our library10.1016/j.cell.2020.02.052
25.
Greaney, A. J. et al. Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies. Preprint at 10.1101/2021.03.17.435863 (2021).
Not in our library
26.
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants · 2020
No notice
27.
Elsner RA, Shlomchik MJ. Germinal center and extrafollicular b cell responses in vaccination, immunity, and autoimmunity. Immunity. 2020;53:1136-1150.
Not in our library10.1016/j.immuni.2020.11.006
28.
Lau AW, Brink R. Selection in the germinal center. Curr. Opin. Immunol. 2020;63:29-34.
Not in our library10.1016/j.coi.2019.11.001
29.
Victora GD, Nussenzweig MC. Germinal centers. Annu. Rev. Immunol. 2012;30:429-457.
Not in our library10.1146/annurev-immunol-020711-075032
30.
Inoue T, Moran I, Shinnakasu R, Phan TG, Kurosaki T. Generation of memory B cells and their reactivation. Immunol. Rev. 2018;283:138-149.
Not in our library10.1111/imr.12640
31.
Taylor JJ, Pape KA, Steach HR, Jenkins MK. Humoral immunity. Apoptosis and antigen affinity limit effector cell differentiation of a single naïve B cell. Science. 2015;347:784-787.
Not in our library10.1126/science.aaa1342
32.
McKean D, et al. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proc. Natl Acad. Sci. USA. 1984;81:3180-3184.
Not in our library10.1073/pnas.81.10.3180
33.
Petersen, M. S. et al. SARS-CoV-2 natural antibody response persists up to 12 months in a nationwide study from the Faroe Islands. Preprint at 10.1101/2021.04.19.21255720 (2021).
Not in our library10.1093/ofid/ofab378
34.
Li, C. et al. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan. Preprint at 10.1101/2021.04.05.437224 (2021).
Not in our library10.1038/s41467-021-24230-5
35.
Turner, J. et al. SARS-CoV-2 mRNA vaccines induce a robust germinal centre reaction in humans. Research Squarehttps://www.researchsquare.com/article/rs-310773/v1 (2021).
Not in our library
36.
Greaney, A. J. et al. The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD. Preprint at 10.1101/2021.04.14.439844 (2021).
Not in our library
37.
Enhanced SARS-CoV-2 neutralization by dimeric IgA · 2021
No notice
38.
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike · 2020
No notice
39.
De Gasparo R, et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 2021;593:424-428.
Not in our library10.1038/s41586-021-03461-y
40.
Xu, J. et al. Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants. Preprint at 10.1101/2021.03.04.433768 (2021).
Not in our library

All 53 references

Cited by papers we hold 21

Muscle abnormalities worsen after post-exertional malaise in long COVID · 2024
No notice
Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans · 2024
No notice
Neutralization, effector function and immune imprinting of Omicron variants · 2023
No notice
Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis · 2022
Not checked
Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies · 2022
Not checked
SARS-CoV-2-Specific Antibody (Ab) Levels and the Kinetic of Ab Decline Determine Ab Persistence Over 1 Year · 2022
Not checked
Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination · 2022
No notice
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants · 2022
No notice
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants · 2022
No notice
Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants · 2022
No notice
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study · 2022
No notice
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection · 2022
No notice
Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection · 2022
No notice
Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection · 2021
No notice
Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities · 2021
Not checked
Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland · 2021
No notice
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells · 2021
No notice
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants · 2021
No notice
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants · 2021
No notice
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination · 2021
No notice

and 1 more

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.